MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/pubmed/fdae007

Медицинская библиотека · Journal of public health (Oxford, England) · 2024

Therapeutic high-dose vitamin D for vitamin D-deficient severe COVID-19 disease: randomized, double-blind, placebo-controlled study (SHADE-S).

Singh Ajay, Rastogi Ashu, Puri Goverdhan Dutt, Ganesh Venkata, Naik Naveen Bal, Kajal Kamal, Kahlon Shubhkarman, Soni Shiv Lal, Kaloria Narender, Saini Kulbhushan, Hazarika Amarjyoti, Mahajan Varun, Singla Karan, Bhadada Sanjay, Soni Vaishali

СтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

efficacy of therapeutic cholecalciferol supplementation for severe COVID-19 is sparingly studied.

OBJECTIVE

effect of single high-dose cholecalciferol supplementation on sequential organ failure assessment (SOFA) score in moderate-to-severe COVID-19.

METHODS

participants with moderate to severe COVID-19 with PaO2/FiO2 ratio < 200 were randomized to 0.6 million IU cholecalciferol oral (intervention) or placebo.

OUTCOMES: primary outcome was change in Day 7 SOFA score and pre-specified secondary outcomes were SOFA and 28-day all-cause mortality.

RESULTS

in all, 90 patients (45 each group) were included for intention-to-treat analysis. 25(OH)D3 levels were 12 (10-16) and 13 (12-18) ng/ml (P = 0.06) at baseline; and 60 (55-65) ng/ml and 4 (1-7) ng/ml by Day 7 in vitamin D and placebo groups, respectively. The SOFA score on Day 7 was better in the vitamin D group [3 (95% CI, 2-5) versus 5 (95% CI, 3-7), P = 0.01, intergroup difference - 2 (95% CI, -4 to -0.01); r = 0.4]. A lower all-cause 28-day mortality [24% compared to 44% (P = 0.046)] was observed with vitamin D.

CONCLUSIONS

single high-dose oral cholecalciferol supplementation on ICU admission can improve SOFA score at Day 7 and reduce in-hospital mortality in vitamin D-deficient COVID-19. ClinicalTrials.gov  id: NCT04952857 registered dated 7 July 2021. What is already known on this topic-vitamin D has immunomodulatory role. Observational and isolated intervention studies show some benefit in COVID-19. Targeted therapeutic vitamin D supplementation improve outcomes in severe COVID-19 is not studied in RCTs. What this study adds-high-dose vitamin D supplementation (0.6 Million IU) to increase 25(OH)D > 50 ng/ml is safe and reduces sequential organ failure assessment score, in-hospital mortality in moderate to severe COVID-19. How this study might affect research, practice or policy-vitamin D supplementation in vitamin D-deficient patients with severe COVID-19 is useful may be practiced.

Для цитирования: Singh Ajay, Rastogi Ashu, Puri Goverdhan Dutt, Ganesh Venkata, Naik Naveen Bal, Kajal Kamal, Kahlon Shubhkarman, Soni Shiv Lal, Kaloria Narender, Saini Kulbhushan, Hazarika Amarjyoti, Mahajan Varun, Singla Karan, Bhadada Sanjay, Soni Vaishali. Therapeutic high-dose vitamin D for vitamin D-deficient severe COVID-19 disease: randomized, double-blind, placebo-controlled study (SHADE-S).. Journal of public health (Oxford, England). 2024. DOI: 10.1093/pubmed/fdae007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.